Payment overview · 2025
General Payments
$24.78
1 reported records · 1 companies
Healthcare provider profile · identity verified
Nicholas James Heezen, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · GREEN BAY, WI · NPI 1114227857
Verified facts
What the public records show
CMS Open Payments records show Nicholas James Heezen, D.O. received $24.78 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.78 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $24.78 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY Normalized: abilify |
Drug | E.R. Squibb & Sons, L.L.C. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1170 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 712 | 187 |
| Losartan Potassium | Losartan Potassium | 491 | 128 |
| Omeprazole | Omeprazole | 481 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 476 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 98 |
| Lisinopril | Lisinopril | 429 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 74 |
| Simvastatin | Simvastatin | 286 | 68 |
| Valsartan | Valsartan | 218 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 64 |
| Metformin Hcl Er | Metformin Hcl | 211 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 59 |
| Metformin Hcl | Metformin Hcl | 206 | 53 |
| Gabapentin | Gabapentin | 201 | 60 |
| Carvedilol | Carvedilol | 193 | 55 |
| Chlorthalidone | Chlorthalidone | 181 | 49 |
| Furosemide | Furosemide | 177 | 56 |
| Warfarin Sodium | Warfarin Sodium | 168 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 32 |
| Allopurinol | Allopurinol | 154 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 44 |
| Meloxicam | Meloxicam | 153 | 38 |
| Eliquis | Apixaban | 150 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 45 |
| Clonazepam | Clonazepam | 140 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 31 |
| Sertraline Hcl | Sertraline Hcl | 127 | 32 |
| Trazodone Hcl | Trazodone Hcl | 126 | 34 |
| Atenolol | Atenolol | 123 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 22 |
| Montelukast Sodium | Montelukast Sodium | 111 | 28 |
| Potassium Chloride | Potassium Chloride | 109 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 38 |
| Ezetimibe | Ezetimibe | 104 | 31 |
| Jardiance | Empagliflozin | 104 | 26 |
| Tramadol Hcl | Tramadol Hcl | 92 | 22 |
| Bupropion Xl | Bupropion Hcl | 90 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 22 |
| Finasteride | Finasteride | 87 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 13 |
| Alprazolam | Alprazolam | 84 | 18 |
| Glipizide Er | Glipizide | 84 | 24 |
| Glipizide | Glipizide | 83 | 24 |
| Donepezil Hcl | Donepezil Hcl | 78 | 12 |
| Fenofibrate | Fenofibrate | 75 | 18 |
| Mirtazapine | Mirtazapine | 73 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 16 |
| Ozempic | Semaglutide | 71 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 20 |
| Alendronate Sodium | Alendronate Sodium | 60 | 20 |
| Glimepiride | Glimepiride | 59 | 15 |
| Famotidine | Famotidine | 58 | 15 |
| Mounjaro | Tirzepatide | 57 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 14 |
| Lorazepam | Lorazepam | 56 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Xarelto | Rivaroxaban | 49 | 12 |
| Buspirone Hcl | Buspirone Hcl | 48 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Lovastatin | Lovastatin | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Celecoxib | Celecoxib | 45 | 11 |
| Baclofen | Baclofen | 44 | 13 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Latanoprost | Latanoprost | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 11 |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Nystatin | Nystatin | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Rytary | Carbidopa/Levodopa | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prednisone | Prednisone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24.78 · 1 records | E.R. Squibb & Sons, L.L.C. | ABILIFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error